Mireca International

Mireca Life Sciences is a biotechnology company dedicated to developing treatments for inherited retinal degenerative diseases, such as Retinitis Pigmentosa. The company's core technology revolves around a proprietary platform of cyclic nucleotide analogs (cGMP analogs) that target the overactivation of protein kinase G, a primary driver of photoreceptor cell death. Their lead candidate, MRP-001, utilizes a specialized liposomal formulation to deliver these analogs effectively to the retina. By inhibiting the pathways leading to cell degeneration, Mireca aims to preserve vision in patients with rare ophthalmic conditions. The company was spun out of the European DRUGSTOP consortium and is based in Germany.